An antigen produced by splicing of noncontiguous peptides in the reverse order.
about
Identification of phosphatidylinositol 4-kinase type II beta as HLA class II-restricted target in graft versus leukemia reactivityAutosomal Minor Histocompatibility Antigens: How Genetic Variants Create Diversity in Immune TargetsDatabase of T cell-defined human tumor antigens: the 2013 updateInvestigation of Serine-Proteinase-Catalyzed Peptide Splicing in Analogues of Sunflower Trypsin Inhibitor 1 (SFTI-1)Computational prediction of cleavage using proteasomal in vitro digestion and MHC I ligand data.A uniform genomic minor histocompatibility antigen typing methodology and database designed to facilitate clinical applications.Graft-versus-host disease: a surge of developmentsC19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients.The 20S proteasome splicing activity discovered by SpliceMet.Pathways of antigen processing.Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum.Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes.Minor histocompatibility antigens and the maternal immune response to the fetus during pregnancyLeukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells.Concurrent detection of circulating minor histocompatibility antigen-specific CD8+ T cells in SCT recipients by combinatorial encoding MHC multimersExploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia.An antigenic peptide produced by reverse splicing and double asparagine deamidationOccurrence and Impact of Minor Histocompatibility Antigens' Disparities on Outcomes of Hematopoietic Stem Cell Transplantation from HLA-Matched Sibling DonorsDriving forces of proteasome-catalyzed peptide splicing in yeast and humans.Amphipols stabilize the Chlamydia major outer membrane protein and enhance its protective ability as a vaccineAllogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after.Definition of Proteasomal Peptide Splicing Rules for High-Efficiency Spliced Peptide Presentation by MHC Class I MoleculesNew lane in the information highway: alternative reading frame peptides elicit T cells with potent antiretrovirus activity.Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantationAugmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation.Proteasomes generate spliced epitopes by two different mechanisms and as efficiently as non-spliced epitopesVaccination with the recombinant major outer membrane protein elicits antibodies to the constant domains and induces cross-serovar protection against intranasal challenge with Chlamydia trachomatis.Minor histocompatibility antigens as targets for immunotherapy using allogeneic immune reactions.Identification of T-cell epitopes for cancer immunotherapy.Diversity of proteasomal missions: fine tuning of the immune response.Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusionToward targeting B cell cancers with CD4+ CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis.Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses.Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein.Towards a liquid self: how time, geography, and life experiences reshape the biological identity.Adoptive T-cell therapy for B-cell malignancies.Insights into MHC class I antigen processing gained from large-scale analysis of class I ligands.Insights into the processing of MHC class I ligands gained from the study of human tumor epitopes.The role of the proteasome in the generation of MHC class I ligands and immune responses.A peptide's perspective on antigen presentation to the immune system.
P2860
Q24652244-727FECA3-B63D-40C4-8CEC-42DAB7632799Q26750999-F59D6185-665E-4C31-BAF7-45979C950382Q27022422-20A1D214-7BC8-4118-B21A-7D7972D3AFBAQ27701655-1EB42BE3-2A41-44F4-9FC8-1628704BACA6Q30665275-03EEDCE6-3485-4CC6-8A86-56CB22B14F13Q33267303-023DBD56-B2C9-435A-959D-89B0D1B4DBB8Q33290423-14DBB53A-E4E9-476C-8EF4-070B99071600Q33359498-712EBB9B-611D-49FB-982B-54EF77073013Q33627497-EF99D89D-320A-4AAC-92F8-4FC95D29CD9AQ33631854-9047F6F9-EA9A-4A27-91F9-A7DB826A3307Q33648677-0730E824-57F1-41C3-B5F3-3BDD5912A793Q33709766-0F552EC0-1D8B-4E2A-961F-AB7C6350E8B5Q33723635-310767F6-2645-486E-AF88-43E9082911F9Q33931811-1AB1542D-F215-494F-9725-3D7A5D15F29BQ33952256-388E997E-274E-4E31-9692-2912B6E7A8C3Q34163218-80073CC3-6D9E-4337-BA85-14A86C06C31EQ34192290-0BC90BBB-2836-48B8-9142-CF451E6FD3AFQ34314427-53E9D9C4-33E6-4BEE-B043-E1BCE840BB5AQ34347732-E7947BC3-3C3F-4F0D-8243-6110333F01E7Q35042764-39F16128-E726-48C5-B2D1-421E8DD14765Q35446852-96751B3F-1BAF-4A6B-ACE9-52450D5B834AQ35786206-89DD5E9A-A4B4-492C-B43D-1EF7433D257FQ36229113-E9A4BD0A-61EE-4801-9D2E-4AD051C6F59DQ36556944-DDA0825D-32ED-4836-AB87-021D2FE415D7Q36662079-B7F1420D-CD29-4835-A16E-5D0E322E3C79Q36769053-11DF5C13-5156-4EAD-824A-36B1FA3CAF63Q36827004-865F6791-CE44-42F5-BE62-F69ADA5CE6DAQ36830199-5BF2C778-F83D-40FE-A834-42E43B273DEFQ36870592-25F8346F-EAC9-4181-B591-7EEE8341522FQ36909248-10BDB011-9AF4-4382-B781-FED959105345Q36945852-465DE35B-9159-4298-83A6-1E5B0F2EE53BQ36979992-060E01AF-6052-4E8D-A786-35709B8D20B0Q36994811-8019F110-C108-4CCC-B2FF-3EAF680B7F5BQ37341897-D83749CD-5156-4AD5-9DE7-876FF293CA0EQ37705431-D89DBAAB-D927-4BB0-B83B-C80E10D8D83BQ37810116-031139F5-1740-49C0-892E-5E4D4CEA47F8Q37851048-D79DE359-394C-4622-8CAA-2A96A0CB6BF0Q37851050-52914FCD-4A9A-48A2-8F77-E8E1729C6753Q37851052-7A2563B5-8A8A-4ECB-9420-4F6DB9C173A8Q38162671-03964577-B294-491A-8555-285C217C9D86
P2860
An antigen produced by splicing of noncontiguous peptides in the reverse order.
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
An antigen produced by splicing of noncontiguous peptides in the reverse order.
@ast
An antigen produced by splicing of noncontiguous peptides in the reverse order.
@en
An antigen produced by splicing of noncontiguous peptides in the reverse order.
@nl
type
label
An antigen produced by splicing of noncontiguous peptides in the reverse order.
@ast
An antigen produced by splicing of noncontiguous peptides in the reverse order.
@en
An antigen produced by splicing of noncontiguous peptides in the reverse order.
@nl
prefLabel
An antigen produced by splicing of noncontiguous peptides in the reverse order.
@ast
An antigen produced by splicing of noncontiguous peptides in the reverse order.
@en
An antigen produced by splicing of noncontiguous peptides in the reverse order.
@nl
P2093
P2860
P356
P1433
P1476
An antigen produced by splicing of noncontiguous peptides in the reverse order
@en
P2093
Alexandre Dalet
Benoît J Van den Eynde
Jeffrey K Mito
Marc A Gavin
Nathalie J Vigneron
Pierre G Coulie
Scott S Tykodi
Stanley R Riddell
Suzanne M Xuereb
Vincent Stroobant
P2860
P304
P356
10.1126/SCIENCE.1130660
P407
P577
2006-09-01T00:00:00Z